



AI-Powered Infrastructure: Bridging the Gap to Accessible Healthcare

INVESTOR OVERVIEW
May 2026



Disclaimer

Not an Offer of Securities: This presentation has been prepared by Rocket Doctor AI Inc. (the "**Company**") for informational purposes only. This presentation does not constitute or form part of, and should not be construed as, an offer to sell, or a solicitation of an offer to purchase or subscribe for, any securities of the Company in any jurisdiction, nor shall it or any part of it form the basis of, or be relied upon in connection with, any contract, commitment or investment decision whatsoever. This presentation is not a prospectus, offering memorandum, or other offering document under applicable securities laws of any jurisdiction.

Confidentiality and Distribution: This presentation is confidential and is intended solely for the use of the person to whom it has been delivered. The information contained herein may not be reproduced, redistributed, or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose, without the prior written consent of the Company. By accepting this presentation, the recipient agrees to be bound by these confidentiality obligations.

Forward Looking Statements: Certain statements contained in this presentation constitute forward-looking information and forward-looking statements within the meaning of applicable Canadian securities legislation (collectively, "**forward-looking statements**"). The words "anticipate," "continue," "estimate," "expect," "may," "will," "project," "should," "believe," "plan," "intend," "target," "forecast," and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this presentation include, without limitation, statements relating to: the Company's business objectives, goals, strategies, and outlook; expectations regarding the development, deployment, and commercialization of the Company's AI-powered healthcare platform and related products, including the Global Library of Medicine (GLM) algorithms, ClinBot, AI Nurse, and Voice AI; expectations regarding future revenue growth, patient visit volumes, and market share; the anticipated expansion of the Company's operations in Canada and the United States; the Company's ability to attract and retain physicians, payer relationships, and healthcare partners; the anticipated benefits and clinical performance of the Company's AI tools; and expectations regarding the healthcare AI market and the Company's competitive position therein.

Forward-looking statements are based on management's current beliefs, expectations, and assumptions as of the date of this presentation, including, without limitation: that the Company's technology platforms will perform as intended and achieve expected clinical outcomes; that the Company will be able to maintain and expand its existing payer relationships, including in-network contracts with Medicare, Medicaid, Medi-Cal, and commercial payers; that the Company will be able to obtain the capital required to fund its operations and growth plans on acceptable terms and in a timely manner; that provincial and state regulatory environments will remain conducive to virtual care delivery; that the Company will retain its key management, medical, and technical personnel; that there will be no material adverse changes in legislation, regulation, or government policy applicable to the Company's business in Canada, the United States, or elsewhere; that no national or regional disasters, acts of war, terrorism, or public health emergencies will materially disrupt the Company's operations; and that macroeconomic conditions, including inflationary pressures, interest rate movements, and foreign currency fluctuations, will not materially adversely affect the Company's business or financial performance.

Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to differ materially from those anticipated or implied by such statements. Such risks and uncertainties include, without limitation: the Company's ability to raise additional capital as needed and on acceptable terms; the Company's limited operating history and history of operating losses; the uncertainty that the Company's AI and digital health platform will achieve broad physician and patient adoption; the risk that the Company's proprietary GLM algorithms and AI tools may not perform as described or may produce inaccurate clinical outputs, which could expose the Company to professional liability and reputational harm; the risk of cybersecurity incidents, data breaches, or failure to comply with applicable privacy legislation, including the *Personal Information Protection and Electronic Documents Act* (PIPEDA) in Canada and the Health Insurance Portability and Accountability Act (HIPAA) in the United States; the risk that healthcare regulatory authorities in Canada, the United States, or other jurisdictions may impose restrictions on, or require approvals for, the Company's AI-based clinical tools; the risk that payer relationships may be terminated, renegotiated at less favorable terms, or subject to reimbursement policy changes that reduce the Company's revenues; the risk of increased competition from well-capitalized incumbents and new entrants in the digital health and healthcare AI space; the Company's dependence on key personnel and medical advisors, the loss of whom could adversely affect the Company's operations; the risk that the Company will not be able to protect its intellectual property rights or that third parties will assert intellectual property claims against the Company; risks relating to physician licensing and credentialing requirements across multiple jurisdictions; risks related to the integration and performance of acquired or licensed technologies; fluctuations in foreign currency exchange rates, in particular between the Canadian dollar and the U.S. dollar; and general economic, market, and business conditions in Canada, the United States, and globally.



Disclaimer

These and other risks are described in the Company's continuous disclosure documents available on SEDAR+. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect management's expectations only as of May, 2026, the date of this presentation. The Company does not undertake any obligation to update or revise any forward-looking statement to reflect new information, future events, or changed circumstances, except as required by applicable securities legislation.

Past performance of the Company is not indicative of, and should not be relied upon as a guide to, future performance.

Market and Industry Data: Market and industry data contained in this presentation is based upon information, surveys, or studies conducted by independent third parties, independent industry publications, or the Company's own knowledge of and experience in the markets in which it operates. While the Company has no reason to believe that such information is false or misleading in any material respect, market and industry data is subject to variation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties inherent in any statistical survey. None of the market or industry data from third-party sources referred to in this presentation has been independently verified by the Company or any of its directors, officers, or representatives. Valuations attributed to private companies in this presentation are indicative only and are based on publicly reported financing information; they have not been independently verified and are subject to significant uncertainty.

Independent Assessment: Recipients of this presentation should make their own independent assessment of the Company and should not rely solely on this presentation for the purposes of making any investment decision. Recipients are encouraged to consult their own legal, financial, tax, and other professional advisors before making any investment decision.

Non-GAAP measure: This presentation contains a financial measure that has not been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), which is referred to herein as a "non-GAAP financial measure." Specifically, this presentation presents Annual Recurring Revenue ("**ARR**"), which is a non-GAAP financial measure. ARR does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. This non-GAAP financial measure should not be considered in isolation or as a substitute for, or superior to, financial measures calculated in accordance with IFRS. The Company defines ARR as the total value, measured in U.S. dollars, over the preceding twelve months of: (i) all revenues recognized by the Company in accordance with IFRS during that period; plus (ii) all revenue commitments from customers that are contracted but have not yet been recognized as revenue under IFRS, in each case, stemming from or related to all ongoing revenue sources. ARR has two components: IFRS-recognized revenue and contracted-but-unrecognized revenue. The most directly comparable IFRS financial measure to ARR is revenue as reported in the Company's financial statements. Management presents ARR because it believes ARR provides investors with a more complete picture of the Company's anticipated recurring revenue base than IFRS revenue alone. ARR reflects contracted commitments from existing customers that management expects to recognize as revenue in future periods, and provides a year-over-year comparison intended to assist in measuring revenue growth and the quality of the Company's revenue streams. ARR is presented in U.S. dollars (USD). The Company's IFRS financial statements are prepared in Canadian dollars (CAD). Figures expressed in different currencies are not directly comparable without reference to the applicable exchange rate. Readers should exercise caution when comparing the ARR figure to IFRS revenue figures presented in this document, which are stated in CAD.





A provider-centered platform built for scalable care delivery

We bring together trusted AI, care delivery solutions, payer access, and patient demand to help providers deliver better care at scale.



Introductions



Dr. Essam Hamza
CEO, Rocket Doctor AI Inc.



Dr. William Cherniak
Founder & CEO, Rocket Doctor Inc.



AI Built by Doctors, for Doctors

- **Trust and Accuracy** - built by practicing physicians with deep understanding of front-line clinical workflows
- AI powered software for the **full patient journey**
- **GLM** - Proprietary algorithms and logic with peer reviewed clinical content, **curated AI**
- **Portability** of GLM into multiple settings - Chatbot; Voice AI; Nurse triage services. API's to integrate into 3rd parties
- Proven **Virtual Emergency Department** (ED) Diversion Model
- **Plug-and-play** platform for physician groups and health systems to rapidly launch or expand virtual care services
- Platforms **ready for commercialization** and **revenue producing** - US growth (~3% of revenues in US in 2025)

Built with compliance, security and scalability in mind.



Our Team

Led by Technology & Healthcare Experts



Essam Hamza, MD CCFP
CEO, Rocket Doctor AI



**Kevin Peterson, MD, MPH,
FRCS(Ed), FAAFP**
Co-Founder & CMO,
Rocket Doctor AI



Richard Atkins
COO, Rocket Doctor AI



**William Cherniak, MD
MPH, CCFP(EM), DABFM**
Founder & CEO,
Rocket Doctor



Harry Cherniak
Co-Founder, COO &
Privacy Officer,
Rocket Doctor



**George Mastoras,
MD, FRCPC**
Canada Medical Director,
Rocket Doctor



Pamela Lai, MD
Director of Clinical
Partnerships, Rocket Doctor



Dr. Evan Ou, MD
US Medical Director,
Rocket Doctor



Healthcare is complex.

Most AI isn't built for It.



Soaring Costs

\$100B+ lost to misdiagnosis;¹



Shrinking Access

Fewer doctors, faster visits, rising burnout.



Misinformed Care

Millions of Americans are affected by misdiagnoses every year²



Data Overload

Doctors absorb data from multiple sources to make decisions.



Administrative Burden

40% of time spent on physician admin³

1. AARP. (2023, August 15). [The cost of a wrong diagnosis](#). AARP.


2. Patients for Patient Safety Canada. [Diagnosis error is a huge patient safety problem. We need more proof.](#)

3. Healthy Debate (2024, November 11) [Beating Administrative Burden - How Digital Health Tools Can Save Administrative Medicine](#). Lino Lagrotteria





A connected suite of AI-solutions for better care delivery



Empowering providers to start, operate & grow

We remove the friction that makes it difficult for providers to deliver modern care.



Start faster

Providers can onboard and begin seeing patients quickly with virtual clinics



Operate more efficiently

AI-powered tools support intake, visits, documentation, and follow-up



Reach more patients

Built-in patient access and payer relationships help drive utilization



Enhance care with AI

AI supports clinical workflows without replacing providers



Expanding Healthcare Access across North America



AB, BC, ON

750,000+ Patients Seen
350+ Physicians



CA, MD, NY

~21M
in-network patients



Humana

Anthem 



Where We Drive Revenue — ~ARR \$2.79M**



Direct to Consumer
~\$2.27M/year

US and Canadian physicians booking virtual appointments.

Average of 17% fee/CA appt

US\$25 flat fee/US appointment



Partnerships
~\$365K/year

Pharmacies, allied health partners and independent provider associations.

\$250 fee, \$250/month for support

\$3,000 for device enabled stations

IPA's send us patients, lowering our CAC



Platform
~\$155K/year

Monthly fee paid by MDs on the platform.

US\$25-\$75 / month per MD depending on specialty and geographic location.

Q4 2025* **Key Financials**

\$0.7 million revenue

84% gross margin

**Q4 Audited figures as of April 30, 2026*

***ARR is a non-GAAP financial metric please refer to the disclaimer*



Growth and Traction

2025 Revenues (<3% from US in 2025)



Total Number of Completed Patients Visits



Our Moat

Established Provider, Payer, Credentialing, and Revenue Operations Infrastructure built over 2-3 years

In-network across multiple U.S. states and Canadian provinces, with growing access to covered lives, physicians, and patients.



Credentialing workflows

Onboarding physicians in months, built through years of operating experience



Multi-payer access

Including Medicare Advantage, Commercial, Medicaid, and Canadian provincial care



Revenue operations

Supporting billing, collections, and visit-based care delivery



Our leadership team of top MDs fuels growth & clinical expertise



Dr. Zead Said
RD Canada Psychiatry Lead;
University of Sheffield



Dr. Matthew Sakumoto
RD Primary Care Lead; UCSF



Dr. Mike Solemar
RD California Lead; UCSF



Dr. Jesse Wilson
Alberta MD Lead; University of
Saskatchewan



Dr. Jean Challiner
Executive Advisor



Dr. Shawn Ziai
RD BC Lead; UofA



Dr. Taaha Muhammad
RD Canada Substance Use
Services Lead; UofT



Dr. Matthew Sheppard
Atlantic MD Lead; University of
Calgary



Dr. Anjuli Little
RD Ontario Lead, UofT



**Dr. Jennifer
Ashley O'Driscoll**
RD Family Medicine Lead;
UofT



Dr. Paramesha Pillay
RD Canada Pediatrics Lead;
UBC



Dr. Mark Biernacki
RD Alberta Lead; UofA



Dr. Kathryn Gussman
RD US Provider Success
Lead; Geisinger



Dr. Suzanne Caccamese
Maryland MD Lead; Penn State
College of Medicine



Dr. Joe Amirault
RD Atlantic Canada Lead;
MUN



Dr. Neil Kumar
MD Lead, British Columbia,
University of British Columbia
MD, CCFP



Dr. Sudha Kumar
California Psych MD Lead;
Boston University




Rocket Doctor AI enables clinical intelligence, virtual care, and voice AI in one trusted ecosystem



Triage technology for integration

Acquired by Amazon (2019) for Amazon Care; digital health clinical content via APIs that can be used by EHRs, telemedicine providers, health chatbots and medical call centers.



AI-powered primary care platform

Lotus Health AI secured \$41 million in funding, including a \$35 million Series A round in February 2026 led by Kleiner Perkins and CRV. No formal valuation, but indicatively **\$140 - \$200 million (private)**.



Hippocratic AI
— Do No Harm —

GenAI agents for healthcare

~\$3.5 billion valuation (private), May 2026 - Valuation reached following its \$126 million Series C funding round. Safety-focused generative AI agents (chatbots) specifically for healthcare industry.



AI-driven synthesis of research and treatment suggestions

OpenEvidence secured a \$250 million Series D funding round in January 2026 that doubled its valuation to approximately **\$12 billion**, reflecting strong investor confidence in its AI-powered medical research synthesis platform used by clinicians.



Conversational AI with early entry into healthcare

SoundHound AI, with an approximately **\$3.19 billion** market cap as of May 2026, is a conversational AI leader just entering healthcare with an estimated 15-25% of revenue from the sector.



Current Value Metrics

Stock Listing

CSE: AIDR / OTC: AIRDF / 939: FRA

Common Shares
Outstanding (b/fd)

95,990,400 / 131,849,550

Insider Ownership

4.12%

Warrants/Options/RSUs
Outstanding

21,577,296 / 7,802,866 / 6,478,988

Market Capitalization

\$57,594,240.00

Outstanding Warrants are exercisable at an average price of CAD \$0.67 (**range CAD \$0.60-\$1.00**) and outstanding Options are exercisable at an average price of CAD \$0.52 (**range CAD \$0.20-\$0.89**).

Market Capitalization is calculated based on total shares issued and outstanding on May 1, 2026, multiplied by the closing price on **May 1, 2026**.





**Join us in empowering providers
to deliver better, more accessible
care.**

Essam Hamza, MD

CEO, Rocket Doctor AI

essam.hamza@rocketdoctor.ai

www.rocketdoctor.ai

Bill Cherniak, MD

CEO, Rocket Doctor Inc.

bill@rocketdoctor.io

www.rocketdoctor.ca